AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CASI
  4. [6-K] CASI Pharmaceuticals, Inc. Current Report (Foreign Issuer)

[6-K] CASI Pharmaceuticals, Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Riscrivi il testo seguente:
Reescribe el siguiente texto:
雼れ潓 韰嶌姢韸鸽ゼ 雼れ嫓 鞛戩劚頃橃劯鞖�:
R茅茅crivez le texte suivant :
Schreiben Sie den folgenden Text um:
Positive
  • None.
Negative
  • None.
Riscrivi il testo seguente:
Reescribe el siguiente texto:
雼れ潓 韰嶌姢韸鸽ゼ 雼れ嫓 鞛戩劚頃橃劯鞖�:
R茅茅crivez le texte suivant :
Schreiben Sie den folgenden Text um:

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August, 2025

 

Commission File Number  001-41666

 

CASI PHARMACEUTICALS, INC.

(Translation of registrant’s name into English)

 

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road, Chaoyang District

Beijing, 100025

People’s Republic of China

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  Form 20-F  x Form 40-F  ¨

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release of CASI Pharmaceuticals, Inc. dated August 4, 2025

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CASI Pharmaceuticals, Inc.
   
  By: /s/ David Cory
  Name: David Cory
  Title: CEO
   
Date: August 4, 2025    

 

 

 

Source:

FAQ

What information is available?

This document appears to contain limited substantive content.
Stock CASI logo
Casi Pharmaceuticals Inc

NASDAQ:CASI

CASI Rankings

#8072 Ranked by Market Cap
N/A Ranked by Dividends
#9 Top Gainer

CASI Latest News

Aug 4, 2025
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)
Jul 21, 2025
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program
May 19, 2025
CASI Pharmaceuticals Provides Business and Clinical Update
May 16, 2025
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
May 12, 2025
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

CASI Latest SEC Filings

Jul 23, 2025
[SCHEDULE 13G/A] CASI Pharmaceuticals, Inc. SEC Filing
Jul 21, 2025
[6-K] CASI Pharmaceuticals, Inc. Current Report (Foreign Issuer)
Jun 20, 2025
[SCHEDULE 13D/A] CASI Pharmaceuticals, Inc. SEC Filing

CASI Stock Data

23.55M
6.67M
48.39%
23.64%
0.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
China
ROCKVILLE